2023 Moores Cancer Center Annual Scientific Retreat
|
The Program will include the special presentation by Dr. John Carethers, Distinguished Professor of Medicine and Vice Chancellor for Health Sciences, the keynote address by Dr. Cheryl Anderson, Professor and Dean of the Herbert Wertheim School of Public Health and Human Longevity Science, breakthrough research presentations from accomplished and junior UC San Diego, Rady Children's Hospital and San Diego State University scientists, a poster session (with poster awards) and a Shark Tank-like competition for a Scientific Retreat Pilot Project award. Visit Website»
|
Napoleone Ferrara, M.D. Awarded the 2023 Keio Medical Science Prize
|
Keio University in Tokyo, Japan’s oldest private university, annually awards the Keio Medical Science Prize to recognize researchers who have made outstanding contributions to the fields of medicine and the life sciences. The Keio is the only prize of its kind awarded by a Japanese university, and nine Keio recipients subsequently have been awarded Nobel Prizes. The 28th Keio Medical Science Prize has been awarded to Moores Member Napoleone Ferrara, M.D. and Kyoto University's Kazutoshi Mori, Ph.D. Read More»
|
Jill P. Mesirov, Ph.D. Awarded Breaking Barriers Award
|
Moores Member Dr. Jill Mesirov was awarded the Breaking Barriers Award, which honors women who have paved the way to inspire girls and women of all ages, at the World Tennis Association's WTA500 Cymbiotika San Diego Open on September 15, 2023. Dr. Mesirov was nominated for the award for her research in genomics (particularly the Human Genome Project), contributions to cancer genomics over the past 3 decades, and dedication to supporting women in science. Congratulations to Dr. Mesirov.
|
University of California Cancer Consortium (UCCC) Molecular Tumor Board (MTB) Fall 2023 Relaunch
|
The UCCC MTB brings together precision oncology experts from across the UC system to share available biomarker-driven therapies for individual patients and ensure awareness of the latest cutting-edge treatment options in cancer care. Read More»
|
Ludmil Alexandrov, Ph.D. Lead PI on New U01: Mapping Immuno-genomic Drivers of the Head and Neck Pre-cancer Invasive-disease Transition
|
This pre-cancer U01 proposal, submitted by Moores Members Ludmil Alexandrov, Ph.D., J. Silvio Gutkind, Ph.D., and Scott Lippman, M.D., received a perfect score and will be funded at 100% ($2.5M direct; $3.95M total). The project will illuminate the molecular and cellular events required for a head and neck pre-cancer to convert into an invasive cancer by (1) mapping the genetic and immune changes in 300 head and neck pre-cancers, (2) comparing these changes between patients who developed and that never developed cancer, and (3) evaluating biomarkers predictive of pre-cancer progression using an established mouse model. The project will improve personalized cancer prevention by elucidating opportunities for targeted interventions that can halt the progression of head and neck pre-cancers into invasive cancers.
|
|
|
September 26, 2023 | 12:00 p.m. to 1:00 p.m.
Moores Goldberg Auditorium & Zoom
|
September 28, 2023 | 12:00 p.m. to 1:00 p.m.
Moores Goldberg Auditorium & Zoom
|
October 2, 2023 | 12:00 p.m. to 1:00 p.m.
Moores Goldberg Auditorium & Zoom
|
October 3, 2023 | 12:00 p.m.
Leichtag Biomedical Research Building, Room 107
|
|
|
CRTEC Speed Mentoring Workshop
| October 12, 2023 | 12:00 to 1:00 p.m.
|
Moores Cancer Research Training and Education Coordination (CRTEC) Speed Mentoring Workshops for 2023–2024 will resume Thursday, October 12, 2023. This kick-off workshop will feature Dr. Barbara Parker, Dr. Eyal Oreni, and Dr. Dwayne Stupack. All students, postdocs, and junior faculty are welcome to attend.
|
|
|
FEATURED FUNDING OPPORTUNITIES |
This mechanism provides support to develop and enhance collaborations and resources necessary for a network of organizations to rapidly execute either Phase II or Phase II-linked Phase I (Phase I/II) kidney cancer clinical trials. These trials feature investigations of high-impact, novel therapeutic agents or approaches for the management or treatment of kidney cancer. Applicants must demonstrate a broad understanding of kidney cancer research, which includes knowledge of the current state of clinical studies and priorities related to kidney cancer. Applicants are encouraged to familiarize themselves with the FY23 Overarching Strategic Goals and Focus Areas to prepare an application. Support from this mechanism is to be directed toward consortium infrastructure needs rather than direct support of the trials themselves.
Deadline: Thursday, October 26, 2023
|
MRA is pleased to announce an RFP for pre-clinical, translational, and early clinical research to produce high-impact, near-term advancements in melanoma prevention, detection, diagnosis, and treatment. Proposals must address a shortcoming in translational science (i.e., turning scientific discoveries into tools and/or treatments for high-risk individuals and patients with melanoma). Successful proposals will describe proposed research that applies important basic and preclinical discoveries to the near-term development of clinical trials and studies to improve melanoma detection, prevention, diagnosis, and/or treatment. Proposals for clinical studies to test well-defined and clearly articulated hypotheses are welcome and should be accompanied by a brief protocol synopsis and timeline that includes milestones. Eligibility and deadlines vary, depending on award type.
Deadline: Multiple—depending on award; see RFP for details.
|
For this NOFO, NCI encourages proposed projects that promote transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. These projects should (1) overcome major barriers in cancer biology and/or oncology, using nanotechnology, and (2) feature mechanistic studies to expand the fundamental understanding of nanomaterial and/or nano-device interactions with biological systems. These studies must be relevant to either the delivery of nanoparticles and/or nano-devices to desired and intended cancer targets in vivo and/or characterization of detection and diagnostic devices and sensors in vitro. IRCN awards are expected to produce fundamental knowledge to aid future and more informed development of nanotechnology-based cancer interventions. The clinical translation of these interventions is beyond the scope of this NOFO.
Deadline: November 3, 2023; May 3, 2024; November 4, 2024; May 5, 2025
|
Tower Cancer Research Foundation supports forward thinking research work in Southern California. The Tower Career Development Award supports young investigators to continue their laboratory studies, while improving their ability to secure further funding. The Tower Scientific Advisory Board evaluates award proposals based on the following criteria: novelty of hypothesis; scientific quality; potential for revealing something meaningful about cancer; feasibility of the proposal; evidence of institutional support for the proposed project.
Deadline: November 6, 2023
|
|
|
Cancer Discovery
Trey Ideker, Ph.D. (Structural and Functional Genomics)
|
Nature Immunology
Aaron M. Miller, Ph.D. (Solid Tumor Therapeutics), Bjoern Peters, Ph.D. (Structural and Functional Genomics), and Stephen P. Schoenberger, Ph.D. (Solid Tumor Therapeutics)
|
Gastroenterology
Rohit Loomba, M.D. (Cancer Control Program)
|
|
|
CORT125134-556: A Phase III Study of Relacorilant in Combination with Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (ROSELLA)
|
PI: Ramez N. Eskander, M.D.
NCT: NCT05257408
|
|
|
CLINICAL TRIALS OFFICE TRANSFORMATION INITIATIVE |
-
Posting will commence in the next 2 weeks for new career opportunities that offer pathways to specialize or take on leadership roles integral to the CTO’s transformation and future performance. Communications will be sent to all current CTO employees at the time of posting, and we encourage you to apply for those positions that may align with your unique skillsets and interests.
-
The next CTO Staff Town Hall will be scheduled for mid-October. Please be on the lookout for the calendar invitation.
- Forty-four trials have entered Fast Lane, five of which have been activated to date across the Lung, Breast, GU and Gyn Teams. Thank you to the cross-functional teams across UC San Diego for their outstanding efforts to prioritize these high-priority trials for Moores patients.
-
CTO continues to execute project plans for process and data/technology opportunities. The first round of prioritized changes will be implemented by the end of September, with more to follow. Improvements are anticipated in October, and CTO will highlight these areas of improvement in future communications.
-
CTO encourages you to continue to work with your managers and share your feedback, as it will help to inform future communications and upcoming Town Hall topics.
|
|
|
EQUITY, DIVERSITY, AND INCLUSION (EDI)
|
Predictive Modeling in Biology and Medicine Conference
|
November 17–19, 2023 | University of California, Riverside
|
The conference will showcase recent progress in mathematical and computational modeling of biological systems, model translational predictions in biology and medicine, and data-driven and machine learning methodologies in biology. The conference will not only bring together researchers at different stages of their career to exchange ideas and novel approaches, but also promote interdisciplinary collaborations that target EDI. Indeed, a special sub-workshop on developing EDI for in education and research will be held on the first day, November 17, 2023.
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT (COE) |
National Hispanic Heritage Month
|
Join COE in celebrating National Hispanic Heritage Month from September 15 to October 15, 2023. Below are events and webinars that are open to the entire community. COE looks forward to your participation!
|
- 9/28—ACS Cancer Disparities Forum (Virtual)
-
10/4—Community Health and Resource Fair at the Jackie Robinson Family YMCA (Liver Cancer Awareness Month and Breast Cancer Awareness Month)
- 10/7—Community Outreach at Dia de la Mujer Festival
|
National Hispanic Heritage Month Social Media Spotlights
|
COE is calling all Hispanic and Latine researchers to be featured on social media and in newsletters in honor of National Hispanic Heritage Month. If you would like to participate, then email Maritza Gomez at mag075@health.ucsd.edu and provide (1) your name, (2) your credentials, (3) one to two sentences about what you study/research, and (4) something meaningful to you about your Hispanic/Latine culture. COE looks forward to hearing from you.
|
Cancer Health Equity Collaborative (CHEC) Quarterly Meeting
|
September 28, 2023 | Virtual
|
Join COE for its quarterly Cancer Health Equity Collaborative (CHEC) meeting on Thursday, September 28, 2023, from 10:00 a.m. to 12:00 p.m. This virtual meeting will feature a diverse lineup of speakers who will share their ongoing efforts to promote health equity in California. The agenda includes the Leukemia & Lymphoma Society, the UCSF FANS Study team, the founder of Pink Crescent, and the founder of Gender Phluid Collective.
|
COE Presentation at the Kroc Center
|
Last week, COE had the privilege of presenting at the Kroc Center, during its senior lunch hour, to educate an audience of over 45 attendees on cancer risk factors, the importance of cancer screening, and the current cancer burden in San Diego.
|
Cervical Cancer Quality Improvement Learning Collaborative Recap
|
Last week, COE held the third session of the Cervical Cancer Quality Improvement Learning Collaborative. This session centered on the assessment of cervical cancer prevalence in the border region and strategies for enhancing screening practices in the future. A heartfelt thank-you goes to guest speaker, Alicia Espinoza, from the Office of Border Health, for generously sharing her insights of San Diego County efforts to encourage cancer screening among community organizations and collaborators.
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to sjchristie@ucsd.edu.
To continue receiving our emails, add us to your address book.
|
|
|
|
